Shopping Cart
- Remove All
- Your shopping cart is currently empty
αGalCer-RBD, a conjugate of the potent invariant natural killer T cell (iNKT) agonist α-Galactosylceramide (αGalCer) and the receptor-binding domain (RBD), serves as a self-adjuvanting lipoprotein that exhibits strong potential as a COVID-19 vaccine candidate. This compound effectively induces immunity against SARS-CoV-2 and its variants of concern by promoting the development of RBD-specific, cytokine-producing T cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | αGalCer-RBD, a conjugate of the potent invariant natural killer T cell (iNKT) agonist α-Galactosylceramide (αGalCer) and the receptor-binding domain (RBD), serves as a self-adjuvanting lipoprotein that exhibits strong potential as a COVID-19 vaccine candidate. This compound effectively induces immunity against SARS-CoV-2 and its variants of concern by promoting the development of RBD-specific, cytokine-producing T cells. |
Molecular Weight | 1119.6 |
Formula | C60H118N4O14 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.